### In vitro / physico-chemical Data <a id="invitro-and-physico-chemical-data"></a>

A literature search was performed to collect available information on physicochemical properties of moxifloxacin. The obtained information from literature is summarized in the table below. 

| **Parameter**   | **Unit** | **Value** | Source                                     | **Description**                                 |
| :-------------- | -------- | --------- | ------------------------------------------ | ----------------------------------------------- |
| MW              | g/mol    |  401.4         | [Willmann 2019](#main-references)               | Molecular weight                                |
| pK<sub>a</sub> (acid) |          | 6.25          | [Langlois 2005](#main-references)         | Acid dissociation constant                      |
| pK<sub>a</sub> (base) |          | 9.29          | [Langlois 2005](#main-references)         | Acid dissociation constant                      |
| Solubility (pH) | mg/mL         | 2.9          | [U.S. Pharmacist 2023](#main-references)               | Aqueous Solubility                 |
| Solubility (pH) | mg/mL         | sparingly soluble in water         | [Willmann 2019](#main-references)               | Aqueous Solubility                |
| logMA            |          | 1.8          | [Willmann 2019](#main-references) | Membrane affinity |
| logP            |          | 0.6          | [Willmann 2019](#main-references) | Partition coefficient between octanol and water |
| logP            |          | 1.04          | [Edginton 2009](#main-references) | Partition coefficient between octanol and water |
| logP            |          | 0.832          | [Litjens 2022](#main-references) | Partition coefficient between octanol and water |
| fu              | %        | 50          | [Edginton 2009](#main-references)                | Fraction unbound in plasma                      |
| fu              |         | 0.606          | [Litjens 2022](#main-references)                | Fraction unbound in plasma                      |
| fu              | %        | 50-60         | [Willmann 2019](#main-references)                | Fraction unbound in plasma                      |
| B/P ratio       |          | 1.10          | [Litjens 2022](#main-references)                | Blood to plasma ratio                           |
| Passive permeability     | 10E-6 cm/s         | 11.5          | [Litjens 2022](#main-references)                | Passive permeability (Caco-2)                           |

### Clinical Data  <a id="clinical-data"></a>

A literature search was performed to collect available clinical data on moxifloxacin in healthy adults.

#### Model Building <a id="model-building"></a>

The following studies were used for model building (training data):

| Publication                 | Arm / Treatment / Information used for model building |
| :-------------------------- | :---------------------------------------------------- |
| [Stass and Kabitza 1999](#main-references) | Healthy Subjects with a single IV dose of 400 mg           |
| [Stass and Kabitza 1999](#main-references) | Healthy Subjects with a single PO dose of 400 mg           |
| [U.S. Food and Drug Administration 2016](#main-references)                         | Healthy Subjects with IV doses of  400 mg QD                                                  |
| [U.S. Food and Drug Administration 2016](#main-references)                         | Healthy Subjects with PO doses of  400 mg QD                                                  |
| [Sullivan 1999](#main-references)                         | Healthy Subjects with PO doses of  400 mg QD                                                   |

#### Model Verification <a id="model-verification"></a>

The following studies were used for model verification:

| Publication                 | Arm / Treatment / Information used for model building |
| :-------------------------- | :---------------------------------------------------- |
| [Siefert 1999](#main-references) | Healthy Subjects with a single IV dose of 100 mg          |
| [Siefert 1999](#main-references) | Healthy Subjects with a single PO dose of 100 mg          |
| [U.S. Food and Drug Administration 2000](#main-references) | Healthy Subjects with a single IV dose of 400 mg (Study PH 27517/0139)         |
| [U.S. Food and Drug Administration 2000](#main-references) | Healthy Subjects with a single PO dose of 400 mg (Study PH 27517/0139)         |
| [U.S. Food and Drug Administration 2000](#main-references) | Healthy Subjects with a single PO dose of 60 mg (Study PH 26024/0101)        |
| [U.S. Food and Drug Administration 2000](#main-references) | Healthy Subjects with a single PO dose of 60 mg (Study PH 26024/0101)         |
| [U.S. Food and Drug Administration 2000](#main-references) | Healthy Subjects with a single PO dose of 100 mg (Study PH 26024/0101)         |
| [U.S. Food and Drug Administration 2000](#main-references) | Healthy Subjects with a single PO dose of 200 mg (Study PH 26024/0101)         |
| [U.S. Food and Drug Administration 2000](#main-references) | Healthy Subjects with a single PO dose of 400 mg (Study PH 26024/0101)         |
| [U.S. Food and Drug Administration 2000](#main-references) | Healthy Subjects with a single PO dose of 600 mg (Study PH 26024/0101)          |

